Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Dosage Regimens: Designs and Approaches01:28

Dosage Regimens: Designs and Approaches

188
Designing a dosage regimen, which refers to the manner of drug administration, is a complex process involving the selection of drug dose, route, and frequency. This process is underpinned by pharmacokinetic parameters derived from tests and population averages. These parameters are then tailored to patient-specific variables such as diagnosis, demographics, and allergy status. Once therapy commences, therapeutic response monitoring is critical and achieved through clinical and physical...
188
Therapeutic Drug Monitoring: Overview and Classification01:16

Therapeutic Drug Monitoring: Overview and Classification

204
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
204
Dose Size and Dosing Frequency: Determination Methods01:21

Dose Size and Dosing Frequency: Determination Methods

177
Determining the optimal dose size and dosing frequency in pharmacotherapy is crucial for achieving therapeutic effectiveness while minimizing adverse effects. This article explores the methodologies employed in determining these parameters, focusing on their significance and interplay to tailor dosing regimens.Dose Size: Dose size refers to the amount of a drug administered in a single dose. It is determined based on the drug's pharmacodynamics and pharmacokinetics properties and...
177
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

130
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
130
Determination of Multiple Dosing Parameters: Loading and Maintenance Doses01:25

Determination of Multiple Dosing Parameters: Loading and Maintenance Doses

136
A loading dose is an essential pharmacological strategy to rapidly achieve the target plasma drug concentration necessary for an immediate therapeutic effect. This approach is especially critical for drugs characterized by slow absorption or extended half-lives, where delaying therapeutic plasma levels could compromise treatment outcomes. By administering a loading dose, clinicians ensure a prompt onset of drug action, even for agents with complex pharmacokinetic profiles.Achieving steady-state...
136
Rational Dosage Regimen: Maintenance Dose and Loading Dose01:24

Rational Dosage Regimen: Maintenance Dose and Loading Dose

5.1K
A rational dosage regimen considers a drug's pharmacokinetics, including its absorption, distribution, metabolism, and elimination from the body. By understanding these factors, the appropriate dosage can be determined, and the dosing schedule can be designed to achieve and maintain the desired therapeutic effect while minimizing adverse effects.
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady...
5.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

RIPK1 inhibition reduces biliary injury and fibrosis in primary sclerosing cholangitis.

Science advances·2025
Same author

Management of patients with type 2 diabetes and MASLD: An overview and joint statement.

Diabetes & metabolism·2025
Same author

Global research initiative for patient screening on MASH (GRIPonMASH) protocol: rationale and design of a prospective multicentre study.

BMJ open·2025
Same author

Factors associated with high costs of patients with metabolic dysfunction-associated steatotic liver disease: an observational study using the French CONSTANCES cohort.

Clinical diabetes and endocrinology·2024
Same author

Reply: Concerns regarding the use of Fatty Liver Index in studies of lean NAFLD.

Hepatology (Baltimore, Md.)·2024
Same author

The NAFLD burden on mortality and morbidities in general population: A community-based longitudinal study (NASH-CO study).

Liver international : official journal of the International Association for the Study of the Liver·2023
Same journal

Effectiveness and safety of mirikizumab in multirefractory ulcerative colitis: analysis from a real-world cohort.

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver·2026
Same journal

Novel approaches to liquid biopsy in pancreatic cancer.

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver·2026
Same journal

GLP-1 receptor agonists in pediatric obesity.

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver·2026
Same journal

An unusual gastric mass in a patient with human immunodeficiency virus infection.

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver·2026
Same journal

Fibrate therapy in primary sclerosing cholangitis: missing data on lipids, interactions, and cancer risk.

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver·2026
Same journal

Pharmacovigilance of drug-induced microscopic colitis: time to consider exposure duration and dechallenge completeness.

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver·2026
See all related articles

Related Experiment Videos

Optimizing DAA management in daily practice.

Lawrence Serfaty1

  • 1Assistance Publique Hôpitaux de Paris, Université Pierre et Marie Curie, Service d'Hépatologie, INSERM UMR_938, Hôpital Saint-Antoine, Paris, France.

Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
|October 5, 2013
PubMed
Summary
This summary is machine-generated.

Telaprevir and boceprevir triple therapy offers benefits for genotype 1 infections but requires careful patient management. A checklist approach, focusing on adherence and side effects, is crucial for successful treatment outcomes.

Keywords:
AdherenceAnaemiaBoceprevirDrug–drug interactionEducational nurseSkin rashStopping rulesTelaprevirTriple therapy

Related Experiment Videos

Area of Science:

  • Hepatology
  • Virology
  • Pharmacology

Background:

  • Hepatitis C virus (HCV) genotype 1 infection poses significant health challenges.
  • Telaprevir and boceprevir-based triple therapy have demonstrated efficacy in treating HCV genotype 1.
  • Managing these advanced therapies presents new complexities for clinicians.

Purpose of the Study:

  • To outline a practical checklist approach for managing telaprevir and boceprevir triple therapy in clinical practice.
  • To highlight key considerations for optimizing patient adherence and treatment outcomes.
  • To emphasize strategies for mitigating treatment failure due to resistance-associated variants.

Main Methods:

  • Review of clinical guidelines and best practices for direct-acting antiviral (DAA) therapy.
  • Identification of critical patient education points and management strategies.
  • Emphasis on proactive management of drug interactions, side effects, and adherence.

Main Results:

  • A structured checklist can facilitate the comprehensive management of triple therapy.
  • Pre-treatment review of drug interactions, duration, outcomes, side effects, and administration is essential.
  • Patient adherence is paramount to prevent the emergence of resistance-associated variants.

Conclusions:

  • Effective management of telaprevir and boceprevir triple therapy requires a systematic approach.
  • Patient education and adherence support are critical for successful treatment and preventing resistance.
  • The role of educational nurses is vital in optimizing patient care and outcomes.